98%
921
2 minutes
20
Introduction: Macrophages (MΦ) modulate both myocardial inflammatory and reparative phases following ischemia-reperfusion (I/R) injury. The mechanistic target of rapamycin (mTOR) is thought to play an important role in MΦ phenotype and functionality, but studies report conflicting net influences suggesting dependence on disease context and downstream signaling. Here, we tested the impact of MΦ with constitutive mTORC1 activation induced by targeted deletion of tuberous sclerosis complex 2 (TSC2) on cardiac responses to I/R injury.
Methods/results: Myeloid TSC2 depleted (MΦ) mice were generated by crossing Lys2 x TSC2. Bone-marrow derived MΦ vs control MΦ had basal increased mTORC1 and reduced mTORC2 activity. MΦ were differentially responsive to stimulation by lipopolysaccharide/IFN-γ or IL-4 , and all disparities were prevented by rapamycin confirming the model. In vivo, MΦ mice were strongly protected against I/R injury, with minimal change in ejection fraction, less LV dilation, hypertrophy, lung edema, or activation of stress/pro fibrotic genes. Mice pre-treated with anti-LY6G Ab to deplete neutrophils were still similarly protected, suggesting that the impact was primarily related to MΦ. MΦ mice had less myocardial pro-inflammatory macrophages (CCR2MHC-II), LY6C monocytes, neutrophils, and CD8 T cells 5 days post-I/R, and fewer CCR2 but more CCR2 MΦ 2 weeks post I/R. Both MΦ in vitro and in vivo post I/R phenotypes were converted to WT by rapamycin, supporting mTORC1 dependence. Lastly, synthesis of glycoprotein nonmetastatic melanoma protein B (GPNMB), a principally MΦ anti-inflammatory secreted protein protective against myocardial infarction was enhanced in MΦ macrophages and hearts following I/R in an mTORC1 dependent manner.
Conclusion: Constitutive macrophage-specific mTORC1 activation via TSC2 deletion reduces pro-inflammatory cell infiltration, increases GPNMB protein expression and preserves heart function following I/R injury. Rapamycin eliminates these effects. These results identify a cardioprotective mTORC1-GPNMB signaling nexus in MΦ in vivo.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12154759 | PMC |
http://dx.doi.org/10.1101/2025.05.29.656917 | DOI Listing |
Cell Death Discov
September 2025
Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Ado-trastuzumab is considered a standard treatment for patients with HER2+ metastatic breast cancer (mBC). Current clinical practices do not reliably predict therapeutic outcomes for patients who are refractory to therapy. Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression and therapeutic resistance, and the use of lncRNAs as tumor biomarkers is becoming more common in other diseases.
View Article and Find Full Text PDFCureus
August 2025
Obstetrics and Gynecology, Maa N Baby Hospital, Surat, IND.
Immune reconstitution inflammatory syndrome (IRIS) is commonly described in individuals recovering from immunosuppression, particularly in HIV-positive patients initiating antiretroviral therapy. However, a similar rebound phenomenon can occur postpartum, a period marked by a shift from an immunotolerant to a pro-inflammatory state. IRIS in this context is underrecognized and may present atypically, complicating timely diagnosis.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFEur J Cancer
September 2025
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Aim Of The Study: The aim of the study is to describe clinical features, treatment approach and outcomes of recurrent/metastatic (R/M) NPC in non-endemic areas MATERIALS AND METHODS: This observational, retrospective and multicenter study was conducted within 36 referral hospital in non-endemic areas including Europe, Jordan, Kuwait, Turkey and United States of America. All NPC patients diagnosed between 2004 and 2016 and with a minimum 12 months of follow-up were included. Data entry started in January 2018 and closed in December 2023.
View Article and Find Full Text PDFNature
September 2025
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
The brain avidly consumes glucose to fuel neurophysiology. Cancers of the brain, such as glioblastoma, relinquish physiological integrity and gain the ability to proliferate and invade healthy tissue. How brain cancers rewire glucose use to drive aggressive growth remains unclear.
View Article and Find Full Text PDF